ASSEMBLY BIOSCIENCES, INC.
ASSEMBLY BIOSCIENCES, INC. (ASMB): 15 pipeline candidates · ~30 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
29.7 months
D/E 0.19 · 6% dilution
Lead: Phase 1
15 candidates
N/A
0 buys · 4 sells (180d)
A transparent, data-derived signal for ASSEMBLY BIOSCIENCES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$462.5M
Cash
$31.1M
Quarterly Burn
$22.1M
Runway
29.7 mo
Revenue
$8.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (15 candidates)
| Drug | Phase |
|---|---|
| abi-1179 | Phase 1 |
| ABI-1179 (1179) | Phase 1 |
| abi-4334 | Phase 1 |
| ABI-4334 (4334) | Phase 1 |
| abi-5366 | Phase 1 |
| ABI-5366 (5366) | Phase 1 |
| abi-6250 | Phase 1 |
| ABI-6250 (6250) | Preclinical |
| abi-7272 | Preclinical |
| ABI-7423 (7423) | Preclinical |
Showing 10 of 15 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
72
Total value held
$378.0M
| Holder | Shares | Value |
|---|---|---|
| gilead sciences, inc. | 4,505,391 | $125.0M |
| janus henderson group plc | 1,698,618 | $47.0M |
| farallon capital management llc | 1,227,590 | $34.1M |
| ra capital management, l.p. | 1,020,410 | $28.3M |
| commodore capital lp | 1,000,000 | $27.8M |
| vanguard capital management llc | 980,894 | $27.2M |
| stempoint capital lp | 370,870 | $10.3M |
| blackstone inc. | 296,855 | $8.2M |
| millennium management llc | 233,650 | $6.5M |
| blackrock, inc. | 202,743 | $5.6M |
Showing top 10 of 72 institutional holders of ASSEMBLY BIOSCIENCES, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ASSEMBLY BIOSCIENCES, INC.'s pipeline?
ASSEMBLY BIOSCIENCES, INC. (ASMB) has 15 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ASSEMBLY BIOSCIENCES, INC.'s lead drug candidate?
ASSEMBLY BIOSCIENCES, INC.'s most advanced tracked candidate is abi-1179 (Phase 1) for Recurrent Genital Herpes Simplex Type 2.
What is ASSEMBLY BIOSCIENCES, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ASSEMBLY BIOSCIENCES, INC. has approximately 29.7 months of cash runway.
What is ASSEMBLY BIOSCIENCES, INC.'s market capitalization?
ASSEMBLY BIOSCIENCES, INC.'s market capitalization is approximately $462.5M.
Who is the CEO of ASSEMBLY BIOSCIENCES, INC.?
Mr. Jason A. Okazaki J.D. is the chief executive officer of ASSEMBLY BIOSCIENCES, INC. (ASMB).
Get the full picture on ASSEMBLY BIOSCIENCES, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.